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Abstract: The ﬁrst total synthesis and developme n to fav a r i e t yo fb i o a c t i v en a t u r a l
products have been accomplished by using carbohydrates as a chiral source. In addition,
practically useful intermediates have been created, analogs of natural products have been
prepared, their structure-activity relationships studied, and the large-scale preparations of
medicinally useful compounds established. The key target molecules have been the ‘‘Big Four’’
antibiotics (macrolides, aminoglycosides,  -lactams and tetracyclines), pyranonaphthoquinone
antibiotics, glycosidase inhibitors, and a side-chain of cephem antibiotics.
Keywords: natural products, antibiotics, total synthesis, enantiospeciﬁc synthesis,
carbohydrates, glycosidase inhibitors
1. Introduction
Anybody can draw a picture, but pictures
painted by famous painters such as van Gogh,
Monet and Picasso are praised as ‘‘art’’. At the
present time, many chemists are able to synthesize
natural products, even those having complicated
structure, using advanced organic chemistry. How-
ever, not all such synthesis is above the mundane
and can thus be raised to the level of ‘‘art’’. Hence,
the unique signiﬁcance of the synthesis and devel-
opment of compounds which possess bioactivity.
The author is of the opinion that ‘‘art’’ is a
sublimate of originality, and has inherent special
characteristics, and, in the 21st century, it should
be recognized as such.
Among bioactive natural products, several
antibiotics, termed the ‘‘Big Four’’, were the fore-
most subject of research at the time the author
started his study of antibiotic synthesis.1) As shown
in Fig. 1, they were the macrolides (oleandomycin
(1), erythromycin A (2), carbomycin, leucomycin
A3 (3), tylosin (4)), aminoglycosides (kanamycin
(5), apramycin (6), saccharocin),  -lactams (thie-
namycin (7)) and tetracyclines (tetracycline (8)).
The author’s group has fortunately succeeded in
completing the total syntheses of 93 diverse bio-
active natural products, including the above-men-
tioned representatives of the big four antibiotics,
and 86 of them represented the ﬁrst total synthesis
of the respective compounds.2) It is noteworthy that
most of optically active compounds have been
synthesized eﬃciently using carbohydrates as chiral
sources, to help determine the absolute structure
and to clarify their structure-activity relationships.
The methodologies devised are now established as
the usual way in the natural product synthesis.2),3)
The ﬁrst total synthesis requires the creation
of original synthesis concepts and methodologies,
including the deﬁnition of the absolute structure
of the bioactive natural products, as well as the
veriﬁcation of their biological activities.
In the present paper, the author introduces
the dynamic as well as elegant parts of his total
synthesis of practically-useful bioactive natural
products, focusing not only on ‘‘art’’ but also on
the signiﬁcance of the total syntheses, and featuring
his concept of ‘‘total synthesis reveals all’’.
2. Syntheses of the big four antibiotics
from carbohydrates
2.1. Total synthesis of macrolide antibiot-
ics and the related macrolactone antibiotics.
When a stone is thrown into a pond, several ripples
doi: 10.2183/pjab/84.87
#2008 The Japan Academy
 1 Graduate School of Science and Engineering, Waseda
University, Tokyo, Japan.
y Correspondence should be addressed: K. Tatsuta, Grad-
uate School of Science and Engineering, Waseda University,
3-4-1 Ohkubo, Shinjuku-ku, Tokyo 169-8555, Japan (e-mail:
tatsuta@waseda.jp).
No. 4] Proc. Jpn. Acad., Ser. B 84 (2008) 87are produced in succession, gradually radiating
outward from the point of entry until they ﬁnally
cover the whole pond. The ‘stone’ in macrolide
synthesis was the news that R. B. Woodward had
begun the total synthesis of erythromycin A (2)i n
1973. His group accomplished the total synthesis in
1981. Some ripples from this point of origin are
represented by Masamune’s methymycin synthesis
in 1977, Corey’s erythronolide synthesis in 1978 and
our syntheses of carbomycin B, leucomycin A3 (3)
and tylosin (4) in 1977 and 1981.1),2) The major
targets, leucomycin A3 and tylosin, were developed
and marketed as medicinally useful antibiotics by
O ¯mura’s group.4)
The ﬁrst total syntheses of the 16-membered
macrolide antibiotics, A26771B, carbomycin B,
leucomycin A3 (josamycin) and tylosin were ac-
complished in our laboratories.1),2) These syntheses
were based on the stereoselective construction of
the carbon skeletons from D-glucose as shown in
Fig. 2.
2.1.1. The ﬁrst total synthesis of 16-membered
macrolide antibiotics. The ﬁrst total synthesis of
tylosin (4) was accomplished by coupling of the
C1-C10 (13)a n dC 1 1 - C 1 5( 14) segments derived
from D-glucose, and the stereo- and regio-selective
introduction of the three sugar moieties (17, 19
and 22) (Scheme 1).5) The C-methyl compound 9,
derived from D-glucose, was converted into the
unsaturated ester 10, which was transformed to the
methyl ketone 13 through a Michael addition with
lithiated methyl methylthiomethyl sulfoxide to give
the branched ester 12. This addition of the lithiated
reagent to the correct position from the desired
side was eﬀectively assisted by the metal chelation
between the isopropylidene oxygen and the carbox-
yl oxygen of the transition state 11,t og i v eo n l y
the natural conﬁguration at C6, as expected. This
step was the ﬁrst key component in completion of
the synthesis.
The aldehyde 14 was also derived from D-
glucose through the branched alcohol. Aldol con-
densation of 13 with 14 gave the unsaturated keto-
ester 15, which was transformed to the seco-acid,
followed by lactonization according to Corey’s
procedure6) to give a tylonolide derivative 16,
following formation of the acetal of the aldehyde
g r o u p .T h ee t h y l e n ea c e t a l16 was submitted to
initial glycosylation with D-mycaminosyl bromide
17, yielding the  -glycoside 18 after methanolysis.
The second glycosylation, accomplished by our
particular method,7) using the glycal of mycarose
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Fig. 1. The representatives of big four antibiotics.
88 K. TATSUTA [Vol. 84,19 plus 1,3-dibromo-5,5-dimethylhydantoin, to give
the 2-bromo-2-deoxy- -glycoside 20 followed by
deprotection and debromination aﬀorded de-myci-
nosyl tylosin (21). The third glycosylation, using
the mycinosyl bromide 22 under Koenigs-Knorr
conditions, followed by deprotection, completed the
total synthesis of tylosin (4). The intermediary 21
was found to show strong antibiotic activities, even
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was not known to possess signiﬁcant activities
against them.8)
2.1.2. The ﬁrst total synthesis of 14-membered
macrolide antibiotics. The author’s group accom-
plished the ﬁrst total synthesis of a 14-membered
macrolide antibiotic, oleandomycin (1) (Scheme
2).9) As mentioned above, this is also based on
the construction of the skeleton from carbohy-
drates, L- and D-rhamnosides, 23 and 24,a n d
then cyclization by intramolecular Horner-Emmons
reaction after esteriﬁcation of the C1-C7 and
C8-C14 segments, 27 and 28, which were derived
from the enantiomeric intermediates 25 and 26.
The sugar moieties 30 and 31 were regio- and
stereoselectively introduced on the aglycone, ole-
andolide (29), to give oleandomycin (1).
The total synthesis of erythromycin A (2)w a s
also accomplished in our laboratories via an original
stereo- and regioselective introduction of sugar
moieties to the aglycone 32 (Scheme 3).10) The
glycosylation to the C3 hydroxyl group of 29 and
erythronolide derivative 33 predictively posed an
extremely diﬃcult problem, due to the low reac-
tivity connected with the sterically crowded nature
of the C3 hydroxyl group and the formation of a
hydrogen bond between its hydroxyl group and C1
carbonyl group. However, our glycosylation, using
the 2,6-anhydro-2-thio sugar 34 worked very eﬃ-
ciently to give the desired  -glycoside 35 in 92%
yield. This was converted to erythromycin A (2)
through desulfurization to give the 2,6-dideoxygly-
coside.
We also developed several other glycosylation
methods to synthesize many natural products.11)
2.1.3. Total synthesis of the macrolactone anti-
biotic, tubelactomicin A. Tubelactomicin A (46)
was isolated from the culture broth of Nocardia sp.
MK703-102F1 and showed strong and speciﬁc
antimicrobial activities against drug-resistant My-
cobacterium sp.12) I t ss t r u c t u r ew a sd e t e r m i n e db y
X-ray crystallographic analysis to be the 16-mem-
bered lactone fused with a trans-decalin skeleton.
Our total synthesis was completed from L-arabi-
nose,13) although, independently, another successful
synthesis was reported.14)
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90 K. TATSUTA [Vol. 84,The stereochemical array of the northern part
of the compound was derived from L-arabinose (36)
(Scheme 4). The lactone 37 was submitted to
stereoselective methylation and reductive ring-
o p e n i n gt og i v et h ed i o l38, possessing functionality
to be the northern part 39. The decalin moiety 43,
the southern part of tubelactomicin A, was con-
structed by intramolecular Diels-Alder reaction.
Citronerol (40) was converted to the triene 41.T h e
stereoselective Diels-Alder reaction to construct
the additional four chiral centers was realized by
heating 41 in xylene, which gave the adduct 42
as a single product. This was converted to 43 to
couple with the northern part 39.
Treatment of the mixture of 39 and 43 under
the conditions of Suzuki coupling gave the tetraene
seco-acid 44 after desilylation.15) The seco-acid 44
was submitted to the macrolactonization by the
Shiina method16) to construct the lactone 45.
Deprotection and selective oxidation aﬀorded (+)-
tubelactomicin A (46).
2.1.4. The ﬁrst total synthesis and determination
of the absolute structure of (+)-cochleamycin A, which
exhibits a unique 10-membered lactone. (+)-Cochle-
amycin A (58) was isolated by the Kirin Brewery
group from a cultured broth of Streptomyces sp. and
showed cytotoxicity against P388 leukemia cells
and antimicrobial activities.17) T h er e l a t i v es t e r e o -
chemistry was elucidated and detected a 5-6-10-6-
membered tetracyclic core (Scheme 5). We accom-
plished the ﬁrst total synthesis of cochleamycin A,
which facilitated determination of the absolute
structure, by using intramolecular Diels-Alder
reaction followed by direct construction of the 10
membered rings,18) which was well-known to be
diﬃcult. After our ﬁrst total synthesis, Roush’s
group reported another synthesis route.19)
For maximum convergency, the acyclic pre-
cursor 52 of the Diels-Alder reaction was con-
structed by connection of two chiral segments, 48
and 50, which were prepared from a small carbo-
hydrate 47 and (S)-1,2,4-trihydroxybutane (49),
respectively, by our previously developed method-
ologies.20) Coupling of 48 and 50 proceeded smooth-
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was selectively reduced to the cis,trans-diene struc-
ture, which was crucial to the construction of the
desired 5-6-membered ring by intramolecular Diels-
Alder reaction. Oxidation of the allylic alcohol gave
the  , -unsaturated aldehyde 52, which was sub-
mitted to intramolecular Diels-Alder reaction in the
presence of Yb(fod)3 at 140  C. The desired adduct
53 was obtained as a single product in good yield.
This intramolecular Diels-Alder reaction produced
four critical stereocenters, as expected. The desired
cyclization of the bromo-aldehyde 54 was accom-
plished with SmI2 to give the 10-6-5-membered
tricyclic product 55 as a single product, comprising
the fully elaborated structure ready for conversion
to the cochleamycin (58). Lactonization of the seco-
acid 56 was realized under Kita’s conditions21) to
aﬀord the 10-membered lactone concomitant with
the formation of the  -lactone ring. The allylic
alcohol of the lactone 57 was oxidized to  , -
unsaturated ketone by exposure to MnO2,f o l l o w e d
by selective acetylation with AcONa and Ac2O
at 60  C to aﬀord (+)-cochleamycin A (58). The
synthetic 58 was identical in all respects, including
the optical rotation, with natural cochleamycin A,
completing the ﬁrst total synthesis to establish the
absolute structure.
Thus, the simplest carbohydrate 47 was eﬃ-
ciently used for the total synthesis. In addition, the
ﬁrst total synthesis of another tetracyclic antibiotic
having a unique  -lactone, tetrodecamycin (59),
was also accomplished by using 47 in our labora-
tories.22)
2.2. Total synthesis of aminoglycoside
antibiotics. The author’s synthetic studies on
antibiotics began with the determination of the
absolute structure and the total synthesis of kana-
mycins (5)( F i g .1 ) . 23) Subsequently, in 1982, the
author had another chance to undertake work on
the total synthesis of aminoglycoside antibiotics,
namely, apramycin (6) and saccharocin (69)
(Scheme 6).
2.2.1. The ﬁrst total synthesis of apramycin and
saccharocin. Apramycin (6) and saccharocin (69)
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92 K. TATSUTA [Vol. 84,are antibiotics active against Gram-positive and
Gram-negative bacteria, including strains resistant
to other aminoglycoside antibiotics. Structurally, 6
and 69 contain the unusual bicyclic aminooctodial-
dose and, in addition, 4-amino-4-deoxy-D-glucose
and D-glucose units respectively.24),25) The ﬁrst
total synthesis of apramycin and saccharocin was
accomplished in our laboratories in 1983.26) Our
starting point was the known aminoglycoside
antibiotic, neamine (60), which had already been
synthesized by us. Neamine was converted into the
aldehyde 61 by eﬀective oxidation of the primary
amino group (Scheme 6). The aldehyde 61 was
converted by our carbon-elongation method to the
acetyl glycal 62. This was submitted to azidonitra-
tion using sodium azide and ammonium ceric
n i t r a t et og i v ea z i d oglycosyl nitrate 63.T h eC 3
position of the dimesylate 64 was selectively
chlorinated to form the 30-chloro compound, which
was dechlorinated with tributylstannane to give the
30-deoxy compound 65. Epimerization of the 60-
hydroxy group, by heating 65 with sodium acetate
trihydrate, yielded the cis cyclic carbamate 66
needed for the apramycin skeleton. Removal of all
protecting groups gave aprosamine (67:Z = H ) ,
which was N-benzyloxy-carbonylated to 67.I nt h e
glycosylation studies on 67, the best result was
realized under modiﬁed Mukaiyama conditions27)
using 4-azido-2,3,6-tri-O-benzyl-4-deoxy- -D-glu-
copyranosyl ﬂuoride (68) to give the glycoside,
subsequently deprotected by hydrogenolysis to
furnish apramycin.
Similarly, saccharocin was synthesized by gly-
cosylation of 67 with 2,3,4,6-tetra-O-benzyl- -D-
glucopyranosyl ﬂuoride.
2.3. Total synthesis and developments of -
lactam antibiotics. The molecular architecture
associated with the  -lactam antibiotics has posed
some of the greatest challenges in synthetic chem-
istry, and this family has provided the stimulus for
development of novel methodologies for construc-
tion of their skeletons and side chains. Among the
cephem antibiotics, the fourth generation has been
especially noteworthy (Scheme 8).
2.3.1. Total synthesis of the  -lactam antibiotic,
(+)-thienamycin. Thienamycin (7)w a sd i s c o v e r e d
in fermentation broths of Streptomyces cattleya and
showed exceptional antibacterial potency and spec-
trum.28) (+)-4-Acetoxy-3-hydroxyethyl-2-azetidi-
none (80) has been well-known as a highly versatile
intermediate for the synthesis of carbapenem
antibiotics, such as thienamycin (Scheme 7).29)
The synthesis of 80 was initiated by the Sankyo
group, followed by the Merck group, and culmi-
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No. 4] Total synthesis and development of bioactive natural products 93nated in the practical preparation by two Japanese
companies, using Noyori-Murahashi’s asymmetric
procedures and chem-enzymatic procedures, respec-
tively.29) The ﬁrst stereocontrolled synthesis of (+)-
thienamycin (7) was reported by the Merck group,
and the transformation of 80 to 7 was also made
more attractive by a second Merck group. Conse-
quently, the synthesis of the azetidinone 80 con-
stitutes a formal total synthesis of (+)-thienamycin
(7).30)
We reported a novel enantiospeciﬁc synthesis
of 80 from a carbohydrate through our developed
skeletal rearrangement and stereoselective epimeri-
zation (Scheme 7).31) Our starting material was
the commercially-available methyl 2-amino-2,6-di-
deoxy- -D-glucopyranoside (70), which has also
been isolated from natural sources.31) Reaction of
70 with o-benzenedisulfonyl dichloride gave the
cyclic sulfonate 71, which was submitted to our
skeletal rearrangement, including ring-contraction
with potassium tert-butoxide. The resulting 3-
formyl-furanoside 72 was oxidized to the carboxylic
acid 73 in 91% yield. Removal of the N-sulfonyl
group of 73 by Birch reduction produced the
corresponding amino acid 74. This was hydrolyzed
and then esteriﬁed to give the furanose 75.O x i d a -
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94 K. TATSUTA [Vol. 84,tion of 75 to the lactone 76 was the key step of
our strategy, although the lactone could not be
obtained under usual oxidation conditions. We
ﬁnally discovered that, on exposure to Ag2CO3/
Celite in benzene, the 75 was smoothly oxidized to
the  -lactone 76 despite the presence of the amino
group.
The next important operation in the synthesis
was to epimerize stereoselectively and simultane-
ously the conﬁgurations at the C2 and C3 positions
of 76. The best result was realized by using DBU in
MeOH to aﬀord predominantly the desired amino
ester 77. This result indicated that the C4 conﬁg-
uration of 76 controlled the stereoselective con-
struction of the C2 and C3 conﬁgurations of 77.
Hydrolysis with 2M NaOH led to the hydroxy acid
78, which was in turn submitted to the  -lactam
formation. For our purpose,aG r i g n a r d - m e d i a t e d
cyclization of the silylated derivative seemed most
promising. Thus, 78 was silylated with trimethyl-
silyl chloride and hexamethyldisilazane (HMDS),
followed by treatment with tert-butylmagnesium
chloride to give the bis-silylated  -lactam 79.
Oxidative decarboxylation by Pb(OAc)4 gave ex-
clusively the desired (+)-4-acetoxy-3-hydroxyethyl-
2-azetidinone (80), with removal of silyl groups.
This was identical in all respects to the authentic
sample.30) Overall, the yield was approximately 35%
in 11 steps from 70. Key steps include our original
skeletal rearrangement with ring-contraction, oxi-
dation of the 2-aminofuranose, and stereoselective
epimerization to the desired conﬁgurations.
2.3.2. Practical preparation of (Z)-2-(5-amino-
1,2,4-thiadiazol-3-yl)-2-methoxy-iminoacetic acid, a
side-chain of the fourth generation of cephem anti-
biotics. Recently, (Z)-7 -[2-(5-amino-1,2,4-thiadi-
azol-3-yl)-2-(alkoxyimino)acetamido]-cephalosporins,
such as cefozopran (89), have been reported as
clinically useful antibiotics having excellent antimi-
crobial activities.32) Their common acyl moiety at
the C7 position corresponds to the Z-isomer (for
example, 88) of 2-(5-amino-1,2,4-thiadiazol-3-yl)-2-
(alkoxyimino)acetic acid (Scheme 8). The E-isomer
is known to be of little value for  -lactam antibiotic
use. Consequently, it was our intention to success-
fully develop a novel general method of entry
into the Z-isomer, even though several methods
have already been reported for the production
of 88.
We devised a novel and concise preparation
directed toward the mass production of the (Z)-
methoxyimino compound: (Z)-2-(5-amino-1,2,4-
thiadiazol-3-yl)-2-(methoxyimino)acetic acid (88)
based on the skeletal rearrangement of the amino-
isoxazoles 81 or 84, and stereoselective formation
of 88 (Scheme 8).33) 3-Amino-5-methoxyisoxazole
(81) was subjected to the skeletal rearrangement
in question. A suspension of methyl chloroformate
and KSCN in acetonitrile was stirred at 70  C
for 30min to give methoxycarbonyl isothiocyanate
in situ, which in turn reacted with 81 to aﬀord
methyl 2-(5-methoxycarbonylamino-1,2,4-thiadi-
azol-3-yl)acetate (83)i n8 6 %y i e l d ,t h r o u g hs k e l -
etal rearrangement of the intermediary thiourea
derivative 82. This reaction mechanism was rea-
sonably supported by the isolation of the similar
intermediate 85 from 3-aminoisoxazole (84). The
compound 85 was also converted to 83 through 86.
Oxidation of 83 gave the 2-oxoacetates 87 (with
DMSO and I2 in the presence of catalytic amounts
of H2SO4) in 83% yield. The moderate yield was
ascribed to puriﬁcation diﬃculties due to their
polar nature. Without isolation of the keto-ester,
the methyl ester 83 was quantitatively converted
into the desired Z-isomer of 2-(methoxyimino)-
acetate. Saponiﬁcation provided the target product
88 in quantitative yield. This was derived to
cefozopran (89), which was marketed in 1995.34)
2.4. Total syntheses and developments of
tetracycline antibiotic and relating antibiotics.
For almost half a century, tetracycline (8)h a sb e e n
widely recognised as a major antibiotic, due to both
its unique structural features as well as antibacte-
rial activities.35) The total synthesis of tetracycline
families was initiated by Woodward’s 6-demethyl-
6-deoxytetracycline synthesis in 1962, followed by
Muxfeldt’s terramycin synthesis in 1968, culminat-
ing Stork’s 12a-deoxytetracycline synthesis in
1996.1),36) However, all these syntheses have been
accomplished only in racemic forms. The total
synthesis of natural ( )-tetracycline (8)r e m a i n e d
an unanswered challenge, despite the remarkable
achievements as described above. In 2000, the ﬁrst
total synthesis of ( )-tetracycline (8)w a sc o m p l e t -
ed in our laboratories using D-glucosamine as a
chiral starting material, which allows stereospeciﬁc
construction of the densely and sensitively func-
tionalized A ring (Scheme 9).37) In 2005, Myers’
group presented a second synthesis of ( )-tetracy-
cline.38)
No. 4] Total synthesis and development of bioactive natural products 95Synthetic studies on related tetracyclic anti-
biotics were also carried out in our laboratories,
and the ﬁrst total synthesis of UCE-6 (110)w a s
accomplished (Scheme 10).39)
2.4.1. The ﬁrst total synthesis of natural ( )-
tetracycline. Anhydrotetracycline (103)w a so u r
ﬁrst target (Scheme 9)37) as it provides a viable
synthetic relay from 103 to tetracycline (8)v i aa
two-step hydration at the 5a,6-position.36) Ar e l i -
able 12a-hydroxylation is required for the synthesis
of 103. The starting-point glucosaminide 90,w h i c h
was prepared from D-glucosamine, was converted
into the selenide 91. Treatment of 91 with borane
followed by H2O2 oxidation stereoselectively gave
the alcohol by simultaneous formation of a new
oleﬁn group, which was benzylated to the oleﬁn 92.
This was submitted to Ferrier reaction with HgCl2
to give the cyclohexanone 93.T h e[ 4 þ 2]c y c l o -
addition of the cyclohexenone, which was derived
from 93 by dehydration, with the butadiene 95 did
not proceed because of the steric repulsion. There-
fore, 93 was epimerized at C2 and dehydrated to
the isomer 94.T h e -hydroxymethyl group was an
important factor for stereospeciﬁc introduction of
the hydroxy group at 12a to give a furan derivative
100. The cycloaddition with 95 in the presence of
2,6-di-tert-butyl-4-methylphenol (DBMP) proceed-
ed from the  -face of 94, regio- and stereoselectively
as expected. This highly-stereoselective reaction
gave a labile adduct, which upon acidic oxidation,
was transformed to the  , -unsaturated ketone 96.
The tandem Michael-Dieckmann type reaction of
96 with the isobenzofuranone 97 gave the tetracy-
clic compound 98.40) One of the key problems of
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96 K. TATSUTA [Vol. 84,this synthesis was the stereoselective introduction
of a hydroxyl group at C12a. Manipulation of the
protective groups of 98 gave the diol 99,w h i c hw a s
adequate to oxidate the right wing. The primary
alcohol of 99 participated in the bromination of C1-
12a oleﬁn to give the desired 100. Treatment of 100
with a mixture of PCC and PDC in dichloro-
methane, followed by puriﬁcation with silica gel,
aﬀorded the aldehyde 101 in 61% yield. This
transformation realized the concurrent oxidation
of primary and secondary alcohols accompanied by
introduction of the C12a hydroxyl group. The
resulting 101 was converted to the nitrile 102 by
a newly-developed method using hydroxylamine
followed by dehydration with 1,10-carbonyldiimida-
zole (CDI). The nitrile 102 was transformed
through 103 and the perhydroxide 104 into ( )-
tetracycline (8), which was identical with natural
( )-tetracycline in all respects, thus completing
the ﬁrst total synthesis. Our tetracycline synthesis
was the ﬁrst to be accomplished, some 50 years
after its structure had been determined.
2.4.2. The ﬁrst total synthesis of the tetracyclic
antibiotic, UCE6. The tetracyclic UCE6 (110)w a s
isolated from fermentation broth of Actinomycetes
strain and possessed strong antitumor ability.41)
From the retrosynthetic perspective, the tetracyclic
skeleton is expected to be accessible by the tandem
Michael-Dieckmann-type reaction of the benzofur-
anone 108 with the cyclic  , -unsaturated ketone
107 (Scheme 10). The 108 was derived from 2-
methylresorcinol and the 107 was prepared by
[4 þ 2] cycloaddition of the cyclohexenone 105 with
the diene 106.39) The coupling of 107 and 108 was
eﬀectively carried out under basic conditions to
give the tetracyclic product, which was aromatized
to the alcohol 109 as a single product, under mild
oxidation conditions concomitant with removal of
one of the O-methoxymethyl groups. Deprotection
of 109 aﬀorded racemic UCE6 (110), which was
identical with the natural product.
3. Total synthesis of pyranonaphthoquinone
antibiotics from carbohydrates
using novel strategies
Pyranonaphthoquinone antibiotics (111–116)
have been shown to possess signiﬁcant antimicro-
bial, antifungal and antitumor activities (Fig. 3).
Structurally, the stereo-alignment of nanaomycin D
(112)i si n c l u d e di nn a n a o m y c i nA( 111)a n dB E -
54238B (116), while that of kalafungin (113)i si n
medermycin (114) and BE-52440A (115). The
representative antibiotics are nanaomycin A (111)
and D (112) ,w h i c hw e r ei s o l a t e da n dd e v e l o p e db y
O ¯mura’s group.42) These unique structures have
drawn attention both for their synthesis using new
methodologies and for the creation of novel bio-
logically active compounds. The author’s group
accomplished the ﬁrst total syntheses of these
antibiotics, and developed a synthetic strategy
for the stereoselective construction of densely-func-
tionalized pyranonaphthoquinones from carbohy-
drates.2)
3.1. The ﬁrst total synthesis of nanaomycin
D and its enantiomer, kalafungin — the ‘‘enan-
tiodivergent’’ total synthesis. Carbohydrates
have been used widely as chiral sources in stereo-
speciﬁc syntheses of natural products, as mentioned
above.3) Although various carbohydrates are avail-
able, in most of them one enantiomer is abundant
while another isomer is diﬃcult to get in much
quantity. Thus, it is hoped that both enantiomeric
chiral synthons in the total synthesis are derived
from only one abundant enantiomer of a carbohy-
drate. During synthetic studies on nanaomycin D
(112) and its enantiomer, kalafungin (113), in our
laboratories, a new methodology was developed to
enable synthesis of both enantiomers from a single
enantiomeric carbohydrate, creating ‘‘enantiodiver-
gent synthesis’’.43) The critical point of the method-
ology was catalytic isomerization of stereocenters
(Scheme 11). On the protected hydroquinone 117,
the isomerization at the C3 position was carried out
to obtain the lactone 118 by elimination-recycliza-
tion equilibrium under basic conditions. Using the
quinone 119, the isomerization at C1 and C4
positions was realized to aﬀord the lactone 120 by
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conditions. This methodology was widely applied
to the construction of pyranonaphthoquinone anti-
biotics. The enantiodivergent synthesis of nanao-
mycin D (112) and kalafungin (113)b a s e do nt h i s
strategy is shown in Scheme 12.43)
Methyl L-rhamnoside (121) was converted
into the 2,3-di-O-carbonyl-4-O-tosyl derivative
122 in 80% overall yield in a one pot reaction, with
trichloromethyl chloroformate and then tosyl chlo-
ride in pyridine (Scheme 12). Treatment of 122
with zinc powder and sodium iodide in reﬂux
aqueous acetonitrile gave the unsaturated alcohol
123. This oleﬁn formation was also developed in our
laboratories. Oxidation of 123 with pyridinium
chlorochromate aﬀorded the stable  , -unsaturated
ketone 124. Michael-Dieckmann condensation of
124 with 4-methoxy-3-(phenylsulfonyl)-1(3H)-iso-
benzofuranone prepared by Hauser’s procedures
gave naphthopyranone 125, which was transformed
to the lactol 126 in three steps. The lactol 126 was
submitted to Wittig reaction, which aﬀorded the
cis-lactone 127 and the trans-hydroxyl ester 128.
The lactone 127 was oxidized to the quinone 129,
which was subsequently de-O-methylated to give
nanaomycin D (112). The hydroxyl ester 128 was
converted to the quinone 130, which was subjected
to the above-mentioned acidic isomerization to
produce kalafungin (113), the enantiomer of na-
naomycin D (112).
3.2. The ﬁrst total synthesis of BE-52440A
and nanaomycin E. (+)-BE-52440A (115)w a s
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Streptomyces strain, by the Banyu group in 2000.44)
The structure was identiﬁed as a dimer of nanao-
mycin derivatives bridged with sulfur (Scheme 13),
although the relative conﬁguration remained un-
known. The ﬁrst total synthesis of 115 was
accomplished by us to help determine the absolute
structure.45) We assumed that 115 would be
biogenetically synthesized by epoxy-opening dime-
rization of OM-173  E( 132), which was isolated
by the O ¯mura group.46) It was possible to obtain
the antibiotic 132 by stereospeciﬁc epoxydation
of pyranonaphthoquinone 131, which could be
derived from the lactone 127 and  -hydroxyester
128 by our enantiodivergent strategy, as mentioned
above.43) The key reaction sequence is a regioselec-
tive epoxy-opening dimerization of the tetra-sub-
stituted 132 with Na2Sb yS N2r e a c t i o no ft h e
intermediary tert-thiolate.
Firstly, both enatiomeric intermediates [( )-
and (+)-131] were selectively synthesized from
the key intermediates 127 and 128. Subsequent
epoxidation aﬀorded (+)- and ( )-OM-173  E
[(+)- and ( )-132]. The one epimer, (+)-132,w a s
hydrolyzed to natural (+)-nanaomycin E (133),47)
which was also isolated by O ¯mura’s group, while
the other ( )-132,o nt r e a t m e n tw i t hN a 2S, was
converted to natural (+)-BE-52440A (115). Thus
their absolute structures were determined.
3.3. The ﬁrst total synthesis of BE-54238B
— the iminoquinone isomerization. We achiev-
ed the enantioselective total synthesis of BE-
54238B (116) to conﬁrm its absolute structure
(Scheme 14).48) The bromo precursor 134 was
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nanaomycin D (112). The 134 was lithiated to
couple with the L-pyroglutamic acid derivative 135
to obtain the ketone 136. After construction of
the pyrrolidine 137,W i t t i gr e a c t i o ng a v et h ecis-
lactone 138 and the trans-hydroxyl ester, in 67%
and 22% yields, respectively. The lactone 138 was
suitable for the synthesis of the natural product
116, while the hydroxyl ester could also be trans-
formed to 138 in high yield by heating with KHCO3
and 18-crown-6 in DMF. Acidic removal of two Boc
groups in 138 was followed by oxidative de-O-
methylation to give the quinone 139.T h i sw a s
eﬀectively cyclized to the hexacyclic product 140
through proton-tautomerization. This was de-O-
methylated by BCl3 to give the re-tautomerized
compound 116, which was identical in all respects
with natural BE-54238B.
4. Total syntheses of useful glycosidase
inhibitors and synthetic organic analysis
of their mode of action
4.1. The ﬁrst total synthesis and chemical
design of useful glycosidase inhibitors. In recent
y e a r s ,m u c ha t t e n t i o nh a sb e e nf o c u s e do nt h e
synthesis and development of glycosidase inhibitors
because of an increasing awareness of the vital role
played by carbohydrates in biological processes.
Therefore, the chemical and biochemical studies on
glycosidase inhibitors may lead to understanding of
the molecular basis of intractable diseases such as
diabetes mellitus, cancer and AIDS, and may also
provide therapeutic approaches to them. As part of
an ongoing program to clarify the mode of action of
glycosidase inhibitors, we have synthesized cyclo-
phellitol (147), nagstatin (158), pyralomicin 1c
(172), valienamine (173) and validamine (174),
and their analogs which have diﬀerent conﬁgura-
tions and functionalities. These syntheses have
featured general methods of entry into the carba-
sugars and their nitrogenous analogs.49)–51)
4.1.1. Cyclophellitol and its analogs. Cyclo-
phellitol (147)i san o v e l -D-glucosidase inhibitor
isolated from culture ﬁltrates of a mushroom,
Phellinus sp., and structurally, is a fully oxygenated
cyclohexane, corresponding to a carba analog of D-
glucopyranose.49) The ﬁrst total synthesis of 147
was mainly based on the stereospeciﬁc intramolec-
ular [3 þ 2] cycloaddition of a nitrile oxide to an
oleﬁn (Scheme 15).50) Its analogs 148–151, includ-
ing the aziridine and thiirane analogs, have also
been enantiospeciﬁcally synthesized in our labora-
tories to clarify their mode of action in glycosidase
inhibition (Table 1).51)
Intramolecular cycloaddition of the oxime 142,
w h i c hw a sd e r i v e df r o mL - g l u c o s e( 141), was
realized by using NaOCl via the intermediary
nitrile oxide 143 to aﬀord the isoxazoline 144 as a
single product. The stereospeciﬁc reaction was
found to be governed by the conﬁguration of the
C2 substituent. The isoxazoline opening was
achieved by reduction of 144 with Raney Ni-W4
in the presence of AcOH to aﬀord the keto-diol,
which was silylated with diethylisopropylsilyl tri-
ﬂate to give the protected ketone 145. The dieth-
ylisopropylsilyl (DEIPS) group was developed in
our laboratories and eﬀectively used as an O-
protecting group,52) because this silyl group was
found to be readily removed under hydrogenolysis
conditions using Pd(OH)2. The mesylate 146 was
subjected to hydrogenolysis followed by epoxida-
tion to give cyclophellitol (147), thereby complet-
ing the ﬁrst total synthesis.
From the fact that cyclophellitol exhibits a
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expected that 1,6-epi-cyclophellitol (148)a n d -
manno analog 151 would inhibit  -D-glucosidase
and  -D-mannosidase activities, respectively.53)
Epi-cyclophellitol (148),  -galacto and  -manno
analogs (150 and 151) were similarly synthesized
from methyl  -D-galactopyranoside. The aziridine
analog 149 and thiirane analogs were also prepared
from 147 and 148. The thiirane analogs having
an S atom showed no bioactivity.53),54)
4.1.2. Nagstatin and its analogs. Nagstatin
(158)i sa nN-acetyl- -D-glucosaminidase inhibitor
isolated from the fermentation broth of Streptomy-
ces amakusaensis.55) Nagstatin (158)a n dav a r i e t y
of its analogs 157–164 were ﬁrst synthesized from
carbohydrates through the inter- and intramolecu-
lar nucleophilic reactions with the imidazole and
triazole moieties to clarify the structure-activity
relationships (Table 1). These compounds were
expected to serve as antagonists of the correspond-
ing  -glycopyranosides. As a starting point, de-
branched nagstatin (157) and its hydroxyl analog
160 were eﬀectively synthesized from 2,3,5-tri-O-
benzyl-L-ribofuranose (152) (Scheme 16).56) Reac-
tion of 152 with lithiated N-tritylimidazole gave
the L-allo (153)a n dL - altro (154) derivatives in a
ratio of approximately 1:1. This lack of selectivity
was expected from unspeciﬁed chelation of 152
and both products were useful for the synthesis of
analogs. De-N-tritylation and the SN2-type intra-
molecular cyclization of 153 or 154 were eﬀectively
realized in a one-pot by reaction with BnSO2Cl in
pyridine to give, preferentially, the 5-O-sulfonate
which, after treatment with Ac2O gave the desired
acetate, which was de-O-acetylated to the nitro-
genous D-talose analog 155 or D-galactose analog
156. The analog 156 was deprotected to the galacto
analog 160 of nagstatin (Table 1). The eﬀective
de-N-tritylation seemed to be aﬀected by the
pyridinium acetate produced. The inversion of the
hydroxyl group in 155 using HN3 aﬀorded the azido
derivative, which was subjected to hydrogenolysis
and N-acetylation, leading to the N-acetyl-D-
galactosamine analog 157, which corresponded to
de-branched nagstatin.
Similarly, nitrogenous D-glucose (159), D-
mannose (161)a n dN-acetyl-D-glucosamine (162)
analogs were eﬃciently prepared from an L-xylo-
furanose derivative. The triazole analogs 163 and
164 were predominantly synthesized from the
aforesaid 152 and L-xylofuranose by reaction with
lithiated triazole.57) The enantiospeciﬁc synthesis
of nagstatin (158) was achieved by introduction
of an acetic acid unit on 157 through the C-
Table 1. Glycosidase inhibitory activities of cyclophellitol (147), nagstatin (158) and their analogs
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cal with the natural product, conﬁrming the abso-
lute structure.
4.1.3. Analysis of mode of action by structure-
activity relationships. With regard to bioactive
compounds, our interest goes far beyond total
synthesis methodologies. Thus we have elucidated
the mechanism of action of various natural products
through detailed investigation of their structure-
activity relationships exploiting our synthetic
organic analysis.2) For example, the glycosidase
inhibiting activities of cyclophellitol (147), 1,6-
epi-cyclophellitol (148), nagstatin (158)a n dt h e i r
analogs, 148–151 and 157–164, were generally
a s s a y e da c c o r d i n gt ot h em e t h o dr e p o r t e db y
Saul et al. and are shown in Table 1.51) In dramatic
contrast to natural cyclophellitol (147), the epi-
epoxide 148 exhibited inhibiting activity only
against  -D-glucosidase. The  -galacto 150 and  -
manno 151 analogs, as expected, showed inhibitory
activity against  -galacto- and  -mannosidases,
respectively, and the  -aziridine analog 149 showed
very high inhibitory activity against  -glucosidase.
Structurally, cyclophellitol and its aziridine analog
149 have quasi-equatorially oriented C1-O and
C1-N bonds, which correspond to the equatorial
C1-O bond of  -D-glucopyranosides, whereas epi-
cyclophellitol and  -manno analog 151 have quasi-
axial C1-O bonds, corresponding to the axial C1-O
bond of  -D-glycopyranosides. Their glycosidase-
inhibiting activities emphasized that the  -a n d -
glycosidases recognized speciﬁcally the C1 positions
and the residual portions as corresponding to
those of  -a n d -glycopyranosides. Consequently,
these glycosidase inhibitors, 147–151,s e r v ea s
antagonists of the corresponding  -a n d -D-
glycopyranosides.
The nitrogenous  -glucosidase inhibitors such
as valienamine (173) and validamine (174)w e r e
synthesized and found to serve as antagonists of the
corresponding  -D-glucopyranoside (Scheme 17).59)
In fact, a validamine derivative, voglibose (175),
was developed and marketed as the anti-diabetes
drug ‘‘Basen’’.60)
It was also found that N-acetyl-D-galactos-
amine analog 157 exhibited strong bioactivity, even
against N-acetyl- -D-glucosaminidase, similar to
nagstatin (158). Consequently, it was expected to
inhibit N-acetyl- -D-galactosaminidase, although
this glycosidase is no longer available. Other
synthesized analogs, 157–164, showed strong in-
hibitory activity speciﬁcally against each of their
corresponding  -D-glycosidases (Table 1).53),56),57)
All analogs possess a quasi-equatorially oriented
C8a-N1 bond, which corresponds to an equatorial
C1-O bond of  -glycopyranosides, due to the fused
imidazole and triazole rings. The conﬁgurations
from C8a to C5 of the analogs parallel the
alignment from C1 to C5 of the corresponding
glycopyranosides. Their substrate-speciﬁc activities
emphasized that the analogs serve essentially
as antagonists of the corresponding stereochemi-
cally oriented  -D-glycopyranosides. These ﬁndings
are similar to those of cyclophellitol and its
analogs.
Thus, these results demonstrated the theoret-
ical possibility of chemically creating inhibitors
against all glycosidases (Table 1).
4.2. The ﬁrst total synthesis of a glucosi-
dase inhibitor, pyralomicin 1c. Pyralomicin 1c
(172) was isolated from a culture broth of Micro-
tetraspora spiralis and found to have novel anti-
tumor properties, including glucosidase-inhibiting
activities.61) We therefore synthesized 172 to
O
BnO
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OH
152
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Scheme 16. Total synthesis of nagstatin.
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The aglycone, pyralomicinone (170), possesses
the 5-hydroxy[1]benzopyrano[2,3-b]pyrrol-4-(1H)-
one structure in which the proton on the pyrrole
nitrogen is slightly acidic. Thus, Mitsunobu con-
ditions would be suitable for the glycosylation step,
which was ﬁrst developed in our laboratories.63)
We had already synthesized 170 during the
ﬁrst total synthesis of pyralomicin 2c, the glucose
analog of 172.64) The carba-sugar moiety 169 was
prepared from L-arabinonic acid  -lactone 165,
which was derived from L-arabinose. This method-
ology had already been developed for synthesis of
progesterone receptor ligands, PF1092s in our
laboratories,65) and applied to the total synthesis
of valienamine (173) and validamine (174).59) The
phenylsulfonate 166 was silylated to the opened
chain enolate 167 in one step by simultaneous
f o r m a t i o no fa ne n o ls i l y le t h e ra n da nO-silyl
secondary alcohol. The SnCl4-promoted aldol con-
densation of 167 resulted in the formation of the
cyclohexenone 168, which was converted to 169
through the introduction of a hydroxymethyl
group. Although 169 possessed three free hydroxyl
groups, the allyl hydroxyl group at C1 was expected
to be more reactive than the others. Both compo-
nents, 169 and 170, were coupled under modiﬁed
Mitsunobu’s conditions to give, predominantly,
the desired product 171 with inversion. Acid
deprotection produced pyralomicin 1c, which was
identical with the natural product.
5. Conclusion
Recent progress in the total syntheses and
development of selected bioactive natural products
is reviewed. Most of the total syntheses that have
been completed in our laboratories have been the
ﬁrst ever accomplished. Establishment of the total
syntheses by use of carbohydrates as chiral sources
created a comprehensive method to investigate a
variety of bioactive natural products. The achieve-
ment of successful results in research is, of course,
of prime importance. Yet, prior to undertaking
research, it is essential that the objectives of the
research are clearly understood and deﬁned. Hence,
it may be no exaggeration to say that the selection
of target molecules decides, above all, the value of
the research itself, particularly with respect to
bioactive natural product synthesis. In essence,
the author believes that the most important factor
is to make the utmost eﬀort towards realizing one’s
goals, that is, to synthesize a target molecule
by one’s own concepts and strategies. However,
through completion of such enterprise and skill,
one can certainly produce the ‘‘art’’, as mentioned
in the Introduction, which becomes manifest in
the reactions and/or products.
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